Skip to main content
logo
Cellromax Science Co., Ltd. (KOSDAQ:471820)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,110.00
-25.00 (-0.60%)
At close: Aug 11, 2026

Cellromax Science Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024
Period EndingMar '26 Dec '25 Dec '24
Revenue
20,97622,18421,630
Revenue Growth
-6.17%2.56%-
Gross Profit
10,13510,54712,284
Operating Income
2,3302,8355,501
Net Income
3,4182,9663,817
Earnings Per Share
302.14261.00367.00
EPS Growth
37.62%-28.88%-

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024
Period EndingMar '26 Dec '25 Dec '24
Cash & Investments
9,2637,70322,732
Total Debt
384.01477.831,498
Net Cash (Debt)
8,8797,22621,234
Net Cash Growth
-44.10%-65.97%-
Net Cash Per Share
782.18633.292041.44

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024
Period EndingMar '26 Dec '25 Dec '24
Operating Cash Flow
2,1301,7856,294
Capital Expenditures
-77.96-78.64-206.22
Free Cash Flow
2,0521,7076,088
Free Cash Flow Growth
-57.55%-71.97%-

Margins
Chart
Fiscal YearTTMFY 2025FY 2024
Period EndingMar '26 Dec '25 Dec '24
Gross Margin
48.32%47.54%56.79%
Operating Margin
11.11%12.78%25.43%
Pretax Margin
15.08%15.56%23.75%
Profit Margin
16.30%13.37%17.65%
FCF Margin
9.78%7.69%28.15%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024
Period EndingAug '26 Dec '25 Dec '24
PE Ratio
13.6024.8014.99
P/FCF Ratio
22.1243.119.40
PS Ratio
2.163.322.65